Owlstone Nanotech, Inc. has announced the receipt of a new order for five development platform systems from a Japanese technology company, and has announced recent appointments of two Asian distributors for its products.
SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.
Amtech Systems, Inc., a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and silicon wafers, today announced that its solar subsidiary, Tempress Systems, Inc., has received approximately $20 million in new solar orders for its diffusion processing systems from two new customers and several existing customers in Asia.
Utilizing Fluidigm Corporation's Dynamic Array and Digital Array integrated fluidic circuits (IFCs), Stanford University researchers to have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.
EcoloCap Solutions Inc., an integrated network of environmentally-focused technology companies utilizing nanotechnology to develop efficient alternative energy solutions, today announced the sale of a NPW-30 unit to R3 Energy LLC.
Thermo Fisher Scientific Inc. today introduced a new application note demonstrating how the Thermo Scientific NanoDrop 3300 enables cancer researchers to study DNA methylation events and polyamine induced DNA G-quadruplex formations by microvolume fluorometry.
RoseStreet Labs Energy, Inc. (RSLE) announced a breakthrough laboratory demonstration of the first known multiband photovoltaic device featuring three distinct light absorption regions integrated into a single layer thin film device.
AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.